Innealta Capital’s Harvard Bioscience HBIO Stock Holding History

Innealta Capital’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-167	Closed	-$4.76K	–	807
2024 Q2	$4.76K	Buy	+167	New	+$5.86K	﹤0.01%	924

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Innealta Capital's HBIO Position: Q3 2024 in Review

Innealta Capital sold out of Harvard Bioscience (HBIO) in Q3 2024, closing a stake of 167 shares — an estimated $4.76K sold.

Innealta Capital first reported a position in HBIO in Q2 2024 and held it in 1 quarter. The position peaked at $4.76K in Q2 2024. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2024.

Innealta Capital reported no remaining Harvard Bioscience position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 167 Harvard Bioscience shares in Q3 2024, an estimated $4.76K.
Innealta Capital first reported a position in Harvard Bioscience in Q2 2024 and held it in 1 quarter.
Innealta Capital's Harvard Bioscience position peaked at $4.76K in Q2 2024.
94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.